Myeloid growth factors: Clinical practice guidelines in oncology™

Jeffrey Crawford, Betsy Althaus, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Mark L. Heaney, Sally Htoy, Dwight D. Kloth, Gary H. Lyman, Wells A. Messersmith, Laura Boehnke Michaud, Sarah C. Miyata, Amy RobbinsMartin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt, Michael K. Wong

Research output: Contribution to journalArticlepeer-review

58 Scopus citations


Chemotherapy-induced neutropenia can cause complications that result in dose reductions or treatment delays that can, in turn, compromise clinical outcomes. Although the prophylactic use of colony-stimulating factors (CSFs) can reduce the risk, severity, and duration of severe and febrile neutropenia, they are not routinely administered to all patients undergoing myelosuppressive chemotherapy because of the costs. Selective use may, however, enhance their cost-effectiveness. These guidelines discuss the preventative or prophylactic use of recombinant human granulocyte-CSF to reduce the incidence, length, and severity of chemotherapy-related neutropenia and and prevent life-threatening complications.

Original languageEnglish
Pages (from-to)188-202
Number of pages15
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number2
StatePublished - Feb 2007


  • Chemotherapy
  • Fever
  • Myeloid growth factors
  • NCCN Clinical Practice Guidelines
  • Neutropenia


Dive into the research topics of 'Myeloid growth factors: Clinical practice guidelines in oncology™'. Together they form a unique fingerprint.

Cite this